HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Levinson, P. D Search for Related Content PubMed Articles by Levinson, P. D

Orlistat with diet was effective and safe for weight loss and coronary risk reduction in obesity

Design
Randomised (unclear allocation concealment^*), blinded (patients, outcome assessors),^* placebo controlled trial with 1 year follow up.

Setting
33 primary care centres in Sweden.

Patients
376 patients between 18 and 75 years of age (mean age 53 y, 64% women) who had a body mass index between 28 and 38 kg/m². Patients had to have 1 of the following: fasting serum glucose concentration 6.7 mmol/l or type-2 diabetes mellitus treated with sulfonylurea or metformin (not insulin); cholesterol concentration 6.5 mmol/l or low density lipoprotein (LDL) cholesterol concentration 4.2 mmol/l on 2 occasions, or lipid lowering medication; or diastolic blood pressure concentration 90 mm Hg on 2 occasions or on hypertension treatment. Exclusion criteria were lactation, pregnancy, or not using adequate contraception; recent myocardial infarction; gastrointestinal surgery for weight reduction; gastrointestinal disorders; pancreatic disease; history of postsurgical adhesions; excessive alcohol intake; substance abuse; or use of systemic steroids or weight or lipid . . . [Full text of this article]

Paul D Levinson, MD

Memorial Hospital of Rhode Island Pawtucket, Rhode Island, USA